Rate Video

BTOG 2022 Summer Meeting | Updates in lung cancer management from the BTOG 2022 Summer Meeting

Riyaz Shah • 8 Jul 2022

BTOG 2022 Summer Meeting

CheckMate-816 NADIM Immuno-Oncology

Riyaz Shah, BSc(Hons), MBBS, FRCP, PhD, Kent Oncology Centre, UK, shares highlights from the BTOG 2022 Summer Meeting, including discussion surrounding the management of early lung cancer and the Phase III CHECKMATE-816 (NCT02998528) and NADIM (NCT03838159) trials showing promising data supporting the neoadjuvant treatment of lung cancer. This interview took place at the BTOG 2022 Summer Meeting congress in London.

UK excels at molecular testing for lung cancer

Riyaz Shah • 29 Jan 2020

Lung cancer molecular testing in the UK

Riyaz Shah • 11 Sep 2022

NSCLC highlights at ASCO 2020

Riyaz Shah • 19 Jun 2020

NICE rejection of osimertinib: what does this mean for EGFR+ NSCLC in the UK?

Riyaz Shah • 29 Jan 2020

Related Videos

Building a clinical research platform to capture and leverage data from cancer care in Germany

Frank Griesinger

Advancing lung cancer therapy: from palliative chemotherapy to immunotherapy

How to discuss immunotherapy as a treatment option with lung cancer patients

Clinical factors in the selection of patients for first-line immunotherapy of lung cancer